Independence Blue Cross is updating its policy on evinacumab-dgnb (Evkeeza®), effective May 27, 2024.
The new version of the policy updates the treated LDL-C levels from ≥ 70 mg/dL to ≥ 100 mg/dL, in accordance with the American College of Cardiology Guidelines.
This updated policy also expands the coverage for pediatric individuals ages 5 – 11 with homozygous familial hypercholesterolemia (HoFH), in alignment with the U.S. Food and Drug Administration (FDA).
For more information, please refer to the following updated policies in Notification, which will be published and available via the Medical Policy Portal starting May 28, 2024:
To find the most updated version of any given policy, please refer to the Medical Policy Portal or simply navigate to the Commercial or Medicare Advantage policy bulletins.